Device/Diagnostics Quarterly Deal Statistics, Q4 2013
A look at financing, M&A, and alliance activity, October–December 2013
Device companies finished 2013 strong, raising $1.2 billion in Q4, the highest quarter total of the year. CVS Caremark’s $2.1 billion buy of Apria’s infusion therapy business was the largest M&A of the year, and late-stage venture rounds dominated the $423 million total in diagnostics funding.
You may also be interested in...
Q4 device financing reached $902 million versus Q3’s $734 million, while device M&A dollar volume increased $19 billion, from Q3’s $4.9 billion. Diagnostics companies raised $750 million, an 85% rise over the previous quarter’s $405 million; although diagnostics M&A totaled just $1 billion, it was the most deal-active quarter of 2014 with 11 transactions.
Three years ago, Covidien signaled its intention to build a gastrointestinal device business with its acquisition of Barrx Medical and its esophageal ablation technology for Barrett’s esophagus. Since then, the industry has been waiting for Covidien to follow through on its strategy to expand its presence in the $3 billion GI market, and that next step came with the company’s recent $860 million acquisition of publicly traded Given Imaging Ltd.
Spine company LDR Holdings Corp. helped signal a turnaround in the spine industry with a successful IPO in October, netting $80 million. Privately, venture capitalists are reporting greater interest in their companies from Wall Street bankers, but should LDR’s success be seen as a strong signal for devices?